(R)-2-(4-异丙基苯基)-N-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙酰胺 | 953778-58-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: (R)-2-(4-异丙基苯基)-N-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙酰胺
• 中文别名: 化合物MK-8998
• 英文名称: MK-8998
• 英文别名: CX-8998；Suvecaltamide；2-(4-propan-2-ylphenyl)-N-[(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl]acetamide
• CAS: 953778-58-0
• 化学式: C₂₀H₂₃F₃N₂O₂
• 分子量: 380.41
• InChiKey: IQIKXZMPPBEWAD-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-methyl-5-(2,2,2-trifluoroethoxy)pyridine 在 盐酸 、 甲醇 、 N-羟基-7-氮杂苯并三氮唑 、 2,2,6,6-四甲基哌啶氧化物 、 copper(II) sulfate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 potassium bromide 作用下， 以 乙醚 、 二氯甲烷 、 氯仿 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.75h， 生成 (R)-2-(4-异丙基苯基)-N-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙酰胺
  参考文献：
  名称：

  WO2007/120729

  摘要：

  公开号：

文献信息

• Pyridyl amide T-type calcium channel antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08263627B2

  公开（公告）日：2012-09-11

  The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

  本发明涉及吡啶酰胺化合物，其是T型钙通道的拮抗剂，并且在涉及T型钙通道的疾病或疾病的治疗或预防中有用。该发明还涉及包含这些化合物的制药组合物以及在涉及T型钙通道的这些疾病的预防或治疗中使用这些化合物和组合物。
• Pyridyl Amide T-Type Calcium Channel Antagonists
  申请人：Barrow James C.

  公开号：US20090275550A1

  公开（公告）日：2009-11-05

  The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

  本发明涉及对T型钙通道具有拮抗作用的吡啶酰胺化合物，其在治疗或预防与T型钙通道有关的疾病和疾病中具有用途。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗与T型钙通道有关的疾病的用途。
• Scalable Asymmetric Synthesis of MK-8998, a T-Type Calcium Channel Antagonist
  作者：Yong-Li Zhong、Jeffrey C. Moore、Michael Shevlin、C. Scott Shultz、Birgit Kosjek、Yonggang Chen、Jacob M. Janey、Lushi Tan

  DOI：10.1021/acs.joc.1c01795

  日期：2022.2.18

  Two scalable and efficient synthetic routes for the synthesis of a T-type calcium channel antagonist MK-8998 were developed from a simple pyridine building block. The key step to set the stereochemistry relied on either chiral rhodium catalyst-mediated asymmetric hydrogenation of an enamide or transamination of an arylketone that provided the corresponding product in high enantioselectivity and high

  从简单的吡啶构建块开发了两种用于合成 T 型钙通道拮抗剂 MK-8998 的可扩展且有效的合成路线。设置立体化学的关键步骤依赖于手性铑催化剂介导的烯酰胺不对称氢化或芳基酮的氨基转移，从而以高对映选择性和高产率提供相应的产物。
• Methods for treating Angelman syndrome and related disorders
  申请人：Cavion, Inc.

  公开号：US11273218B2

  公开（公告）日：2022-03-15

  Provided herein are methods of treating Angelman Syndrome and/or Prader-Willi syndrome, that include administering an effective amount of a T-type calcium channel antagonist to a subject in need of the treatment.

  本文提供了治疗安杰曼综合征和/或普拉德-威利综合征的方法，包括向需要治疗的受试者施用有效量的T型钙通道拮抗剂。
• Treating essential tremor using (R)-2-(4-Isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
  申请人：Cavion, Inc.

  公开号：US11311522B1

  公开（公告）日：2022-04-26

  This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.

  本发明涉及治疗患有或有可能患有一种或多种运动障碍（如本质性震颤、癫痫和/或帕金森病）的哺乳动物的方法和材料。例如，本发明提供了包括一种或多种T型钙通道拮抗剂（如一种或多种Cav3拮抗剂，如CX-8998）的组合物，以及向患有或有可能患有一种或多种运动障碍（如本质性震颤、癫痫和/或帕金森病）的哺乳动物施用此类组合物以治疗该哺乳动物的方法。